TELA Bio, Inc. (TELA) stock
TELANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$0.76+0.00 (+0.07%)
Close on Nov 17, 2026Market cap $34.21MP/E –Yield –
TELA Bio operating margin
Operating margin is operating income as a percentage of revenue.
TELA Bio's operating margin for the twelve months ending Jun 30, 2026 was -42.6%. For fiscal 2025 it was -42.0%, against -49.2% the year before. The highest annual figure on record is -42.0% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -42.0% | +7.2 |
| FY2024 | Dec 31, 2024 | -49.2% | +26.2 |
| FY2023 | Dec 31, 2023 | -75.4% | +18.8 |
| FY2022 | Dec 31, 2022 | -94.2% | +5.8 |
| FY2021 | Dec 31, 2021 | -100.0% | +38.8 |
| FY2020 | Dec 31, 2020 | -138.8% | −14.7 |
| FY2019 | Dec 31, 2019 | -124.1% | +90.9 |
| FY2018 | Dec 31, 2018 | -214.9% | +183.8 |
| FY2017 | Dec 31, 2017 | -398.7% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -48.1% | −3.2 |
| Q1 FY2026 | Mar 31, 2026 | -55.2% | +1.3 |
| Q4 FY2025 | Dec 31, 2025 | -31.9% | +15.5 |
| Q3 FY2025 | Sep 30, 2025 | -36.5% | +12.9 |
| Q2 FY2025 | Jun 30, 2025 | -45.0% | +26.9 |
| Q1 FY2025 | Mar 31, 2025 | -56.5% | −27.5 |
| Q4 FY2024 | Dec 31, 2024 | -47.3% | +24.9 |
| Q3 FY2024 | Sep 30, 2024 | -49.4% | +18.2 |
| Q2 FY2024 | Jun 30, 2024 | -71.9% | −0.4 |
| Q1 FY2024 | Mar 31, 2024 | -29.1% | +65.4 |
| Q4 FY2023 | Dec 31, 2023 | -72.2% | +9.0 |
| Q3 FY2023 | Sep 30, 2023 | -67.6% | +17.4 |
| Q2 FY2023 | Jun 30, 2023 | -71.5% | +26.9 |
| Q1 FY2023 | Mar 31, 2023 | -94.5% | +25.1 |
| Q4 FY2022 | Dec 31, 2022 | -81.2% | +10.2 |
| Q3 FY2022 | Sep 30, 2022 | -85.0% | +9.3 |
| Q2 FY2022 | Jun 30, 2022 | -98.4% | −1.6 |
| Q1 FY2022 | Mar 31, 2022 | -119.6% | +4.1 |
| Q4 FY2021 | Dec 31, 2021 | -91.4% | +27.7 |
| Q3 FY2021 | Sep 30, 2021 | -94.3% | +34.9 |
| Q2 FY2021 | Jun 30, 2021 | -96.7% | +50.6 |
| Q1 FY2021 | Mar 31, 2021 | -123.7% | +50.7 |
| Q4 FY2020 | Dec 31, 2020 | -119.1% | +11.1 |
| Q3 FY2020 | Sep 30, 2020 | -129.2% | +27.5 |
| Q2 FY2020 | Jun 30, 2020 | -147.3% | +79.2 |
| Q1 FY2020 | Mar 31, 2020 | -174.4% | −60.3 |
| Q2 FY2019 | Jun 30, 2019 | -130.2% | – |
| Q1 FY2019 | Mar 31, 2019 | -156.7% | – |
| Q4 FY2018 | Dec 31, 2018 | -226.5% | – |
| Q3 FY2018 | Sep 30, 2018 | -114.1% | – |
See a number that looks wrong?